Back to top

Analyst Blog

Takeda Pharmaceutical Company Limited (TKPYY) recently announced the submission of a new drug application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for its drug Takepron (lansoprazole). The company is seeking approval of a fixed-dose combination of Takepron and low-dose aspirin for treating patients suffering from peptic ulcer.

Patients taking low-dose aspirin to prevent recurrence of cerebral infarction or myocardial infarction are on the rise with Japan’s aging population. We note that the administration of low-dose aspirin may cause disorders such as gastric and duodenal ulcer. Therefore, it becomes very important to prevent the onset of ulcers in the said population group.

Takeda filed the NDA on the basis of a study of bioequivalence between the fixed-dose combination therapy and two pills of Takepron and low-dose aspirin.

We note that Takepron, a proton pump inhibitor, is already approved for the prevention of recurrence of ulcers in patients requiring administration of low-dose aspirin for a long period. The patients have a history of gastric and duodenal ulcer.

We remind investors that a few days back Takeda submitted an NDA for Adcetris (brentuximab vedotin) in Japan for the treatment of adults suffering from relapsed or refractory CD30 positive Hodgkin lymphoma (HL) and relapsed or refractory CD30 positive anaplastic large cell lymphoma (ALCL).

Currently Takeda carries a Zacks Rank #4 (Sell). Comparatively, Lannett Company, Inc. (LCI - Snapshot Report), UCB SA (UCBJF) and Cytokinetics, Inc. (CYTK - Snapshot Report) look better-positioned in the pharma space. They all carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
PANTRY INC PTRY 21.02 +2.09%
INTEL CORP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%